Recent updates to acute coronary syndrome (ACS) management have refined antiplatelet therapy recommendations by balancing ischemic and bleeding risks based on contemporary evidence. Selecting the appropriate P2Y12 inhibitor remains a key component of evidence-based care after ACS. Here is a quick question on the contemporary management of ACS! (Scroll down to answer the question) ##Reference## 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes.
J Am Coll Cardiol. 2025.## ##Disclaimer## The content provided on Docplexus is intended for educational purposes only. While we strive to ensure its accuracy, we make no explicit or implied warranties about the information's suitability, reliability, or adequacy, including data visualization elements and graphics. We do not endorse any medical treatment, product, ideas, or service, including…
